DCPH - Zai Lab Deciphera's Qinlocked OK'd in China for gastrointestinal tumors

The China National Medical Products Administration ((NMPA)) has approved Zai Lab (ZLAB) and Deciphera Pharmaceuticals' (DCPH) New Drug Application ((NDA)) for Qinlock (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumors ((GIST)) who have received prior treatment with three or more kinase inhibitors, including imatinib.Qinlock targets the broad spectrum of KIT and PDGFR? mutations known to drive GIST. Deciphera and Zai Lab are also exploring the use of Qinlock to treat patients with second-line GIST. Deciphera has completed enrollment in Phase 3 INTRIGUE study of Qinlock in patients with second-line GIST, with top-line results anticipated in H2. In May 2020, the FDA approved Qinlock for the treatment of adults with advanced GIST. It is also approved by Health Canada and by the Australian Therapeutic Goods Administration. Zai Lab has an exclusive license agreement with Deciphera for the development and commercialization of ripretinib in Greater China (mainland China, Hong

For further details see:

Zai Lab, Deciphera's Qinlocked OK'd in China for gastrointestinal tumors